<DOC>
	<DOCNO>NCT01934894</DOCNO>
	<brief_summary>This phase II trial combine two agent , cabazitaxel lapatinib , treat patient metastatic breast cancer ( MBC ) metastasize brain . The first portion study determine optimal dose cabazitaxel/lapatinib combination administer patient . After determine optimal dose , patient continue treatment cabazitaxel lapatinib assess response treatment agent .</brief_summary>
	<brief_title>Cabazitaxel Plus Lapatinib Therapy HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases</brief_title>
	<detailed_description>This open-label , non-randomized , Phase II study lead-in safety cohort . Through safety lead-in portion trial define optimal dose cabazitaxel give combination lapatinib patient HER2-positive MBC CNS metastasis . The Phase II portion assess intracranial response rate patient HER2-positive MBC CNS metastasis . Toxicity progression free survival ( PFS ) obtain evaluate . The trial conduct multiple study site SCRI Development Innovations .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>1 . Patients HER2positive MBC unequivocal evidence brain metastasis . 2 . Documented HER2positive tumor status study entry define : Immunohistochemical ( IHC ) score 3+ IHC score 12+ confirmed FISH ( Fluorescence situ hybridization ) positive ( base ASCOCAP guideline 2013 ) FISH SISH ( Silver situ hybridization ) positive ( base ASCOCAP guideline 2013 ) 3 . Patient must least one measurable brain lesion ( define lesion ≥ 5mm cm long dimension ) , T1 weight , gadolinium enhance MRI . Patients may surgical excision brain metastasis provide least one lesion meet follow criterion : Patients brain metastases previously untreated intracranial radiation ( i.e . whole brain radiation therapy [ WBRT ] /partial brain radiation stereotactic radiosurgery [ SRS ] ) must least one intracranial tumor lesion ≥ 5mm . Patients brain metastases previously untreated intracranial radiation ( i.e. , whole brain radiation therapy [ WBRT ] /partial brain radiation stereotactic radiosurgery [ SRS ] ) must least one intracranial tumor lesion ≥ 5mm . Patients brain metastases previously treat WBRT/partial brain radiation must least one intracranial tumor lesion ≥ 5mm must evidence intracranial progressive disease Patients previously treat WBRT/partial brain radiation SRS must least one intracranial tumor lesion ≥ 5mm treated SRS must intracranial disease . Patients previously treat SRS must either demonstrate disease progression ≥ 12 week complete SRS lesion measure ≥ 5mm must least one intracranial tumor lesion ≥ 5mm treated SRS . 4 . Patients receive WBRT/partial brain radiation intracranial metastasis eligible treatment complete ≥28 day prior first dose study drug . 5 . Estrogen receptor ( ER ) progesterone receptor ( PR ) status primary recent tumor assessment must know pending time study registration . Patient 's ER/PR status ( i.e. , positive negative ) influence enrollment requirement . 6 . Patient must receive prior treatment HER2directed therapy trastuzumab , either adjuvant metastatic setting . 7 . Prior treatment lapatinib ( neo ) adjuvant metastatic setting . 8 . Patients without prior chemotherapy MBC eligible provide patient relapsed adjuvant therapy trastuzumab ≤6 month follow completion adjuvant therapy . Otherwise , specific minimum maximum number previous chemotherapy regimen MBC . 9 . Patients must complete cytotoxic chemotherapy ≥21 day ( every 3week regimen ) ≥14 day ( every 2week weekly regimen ) recover come new chronic stable baseline treatmentrelated toxicity order eligible study treatment . Patient must complete biologic therapy ≥3 week 5half life whichever short . Patient must discontinue hormonal therapy minimum 1 day prior first dose study treatment . Patients receive palliative radiation bone , soft tissue disease sit must complete ≥1 week prior first dose study treatment . 10 . Patients must recover ( &gt; 2 week recovery mandate ) acute neurosurgical intervention metastatic CNS disease ( e.g. , resection , shunt placement ) must clinically stable . These patient must residual measurable CNS lesion ( ) follow surgical procedure site serve target lesion . 11 . Patients must neurologically stable , receive steroid , must stable decrease dos corticosteroid and/or anticonvulsant define stable low dos corticosteroid ≥ 5 day prior first dose study treatment . 12 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 2 . 13 . Adequate hematologic , renal , hepatic function . 14 . Adequate coagulation parameter . 15 . Other laboratory testing : Serum magnesium ≥ institutional low limit normal ( LLN ) Serum potassium ≥ institutional LLN 16 . Male patient willing use adequate contraceptive measure . 17 . Female patient childbearing potential , female patient childbearing potential agree use adequate contraceptive measure , breastfeeding , negative serum urine pregnancy test within 72 hour prior start treatment . 18 . Life expectancy ≥12 week . 19 . Ability swallow oral medication . 20 . Willingness ability comply trial followup procedure . 21 . Ability understand nature trial give write informed consent . 22 . Willingness ability comply trial followup procedure . 23 . Ability understand nature trial give write informed consent . 1 . Previous treatment cabazitaxel . 2 . CNS disease require immediate neurosurgical intervention ( e.g. , resection , shunt placement , etc. ) . 3 . Leptomeningeal metastasis site CNS metastasis . Patients parenchymal brain metastasis leptomeningeal metastasis eligible provided meet eligibility criterion . 4 . Peripheral neuropathy ≥Grade 2 ( CTCAE v4.0 ) . 5 . Concurrent treatment radiation therapy , hormonal therapy , biologic therapy chemotherapy allow . Low dose corticosteroid ( ≤30 mg/day prednisone equivalent ) allow . 6 . Concurrent treatment drug know moderate strong inhibitor inducer isoenzyme CYP3A discontinue switch different medication prior start study drug . 7 . Concurrent use St. John 's wort grapefruit/grapefruit juice ≤7 day prior start study drug allow . 8 . Presence active gastrointestinal ( GI ) disease condition opinion investigator interfere significantly absorption , distribution , metabolism , excretion oral therapy ( e.g . ulcerative disease , uncontrolled nausea , vomit ) . 9 . Known diagnosis human immunodeficiency virus ( HIV ) , Hepatitis B ( HBV ) Hepatitis C ( HCV ) . 10 . Presence active cancer , history treatment invasive cancer ≥3 year . Patients stage I cancer receive definitive local treatment curative intent least 3 year previously , consider unlikely recur eligible . All patient previously treat situ carcinoma ( i.e . noninvasive ) eligible , patient history nonmelanoma skin cancer . 11 . Any severe and/or uncontrolled medical condition condition could affect participation study : Symptomatic congestive heart failure ( CHF ) New York Heart Association Class III IV . QTc &gt; 480 m screen ECG ( use Fredericia formula ) Poorly control clinically significant atherosclerotic vascular disease include cerebrovascular accident ( CVA ) , transient ischemic attack ( TIA ) , angioplasty , cardiac vascular stenting past 6 month Active ( acute chronic ) uncontrolled severe infection . Active hepatic biliary disease ( except patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis , stable chronic liver disease per investigator assessment ) . 12 . Known hypersensitivity cabazitaxel drug formulate polysorbate 80 . 13 . Psychological , familial , sociological , geographical condition permit compliance protocol . 14 . Inability unwillingness comply study and/or followup procedure outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HER2-positive breast cancer</keyword>
	<keyword>intracranial metastasis</keyword>
	<keyword>lapatinib</keyword>
	<keyword>cabazitaxel</keyword>
</DOC>